Skip to content
Screener

Kodiak Sciences Inc KOD Stock-Based Comp

Stock-Based Comp at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$243M-3.5%
EyePoint, Inc. logo
EyePoint, Inc.EYPT
$10.4M+51.2%
KLR
Kalaris TherapeuticsKLRS
$580K+55.1%
4D Molecular Therapeutics logo
4D Molecular TherapeuticsFDMT
$4.45M-36.3%
HRO
HarrowHROW
$3.84M-15.8%
PVL
Palvella TherapeuticsPVLA
$3.38M+209%

Other financials

Income statement

See full
Operating income-$59.8M-1.2%
Net income-$58.2M-1.2%
EPS (diluted)-$0.94+13.8%

Balance sheet

See full
Cash & equivalents$169.5M+22.1%
Total debt$56.0M-17.2%
Total equity$112.1M+3.0%
Total assets$306.0M+2.7%

Cash flow

See full
Operating cash flow-$40.0M-37.6%
CapEx$942.0K+249%
Free cash flow-$41.0M-39.5%

Valuation

See full
Market cap$2.84B+556%
Enterprise value$2.73B+592%

Returns & leverage

See full
Return on equity-208.8%+2,306pp
Debt / equity0.5×-0.1×
Current ratio3.5×-1.1×

Where this comes from

Reported directly by Kodiak Sciences Inc in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The source filing: Kodiak Sciences Inc’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:15 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-211951
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Net loss$(58,158)$(57,461)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation4,1094,603
Stock-based compensation12,15515,891
Loss on disposal of long-lived assets8
Non-cash lease impairment expense1,910
Amortization of operating lease right-of-use asset2,2312,125
Changes in assets and liabilities:

Item 1. Financial Statements (Unaudited).

FAQ

What is Kodiak Sciences Inc's stock-based comp?
Kodiak Sciences Inc (KOD) reported stock-based comp of $12.16M in Q1 2026.
How has Kodiak Sciences Inc's stock-based comp changed year-over-year?
Kodiak Sciences Inc's stock-based comp decreased by 23.5% year-over-year, from $15.89M to $12.16M.
What is the long-term trend for Kodiak Sciences Inc's stock-based comp?
Over 4 years (2021 to 2025), Kodiak Sciences Inc's stock-based comp has grown at a -1.0% compound annual growth rate (CAGR), from $61.39M to $58.86M.
What does stock-based comp mean?
Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

Ask your AI about Kodiak Sciences Inc's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude